CSIMarket Company Name, Ticker, Competitors, else..
 
Oculis Holding Ag  (NASDAQ: OCS)
 
Price: $11.3100 $-0.16 -1.395%
Day's High: $11.600000381469727 Week Perf: -7.07 %
Day's Low: $ 11.00 30 Day Perf: -11.29 %
Volume (M): 169,325 52 Wk High: $ 34.47
Volume (M$): $ 0 52 Wk Avg: $20.61
Open: $11.35 52 Wk Low: $10.52



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 60
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -150
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Oculis Holding AG is a Swiss-based biotechnology company that specializes in developing innovative topical treatments for ocular diseases. The company focuses on developing safe and effective treatments that can be administered through eye drops, aiming to improve patient convenience and adherence to therapy. Oculis Holding AG's research and development efforts are guided by advancements in drug delivery technology and a deep understanding of ocular diseases. The company's goal is to provide novel solutions that offer significant benefits to patients in terms of efficacy, safety, and ease of use.


   Company Address: Bahnhofstrasse 20 Zug 6300
   Company Phone Number: 41-711-3960   Stock Exchange / Ticker: NASDAQ OCS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -5.78%    
ESPR        0.95% 
LEGN   -12.33%    
NVS   -15.38%    
ONC   -5.52%    
REGN   -6.9%    
• View Complete Report
   



Clinical Study

Advancements in Ophthalmic Therapeutics Insights from Phase 2 Trials on Privosegtor and Licaminlimab

Published Mon, Sep 22 2025 8:23 AM UTC

In recent years, significant developments in ophthalmic therapeutics have been guided by innovative clinical trials and breakthroughs in drug formulation. Oculis Holding AG, a key player in the global biopharmaceutical sector, has made substantial strides in improving eye care for conditions such as Acute Optic Neuritis (AON) and Dry Eye Disease (DED). This article delves in...
Shares

Oculis Holding AG Reinforces Growth Strategy with Strategic Share Issuance: What Investors Should nKow,

Published Fri, Jan 31 2025 9:00 PM UTC

Oculis Holding AG Expands Capital Base with New Share Issuance: A Strategic Move for Future GrowthIn a significant development for Oculis Holding AG, a global biopharmaceutical company based in Zug, Switzerland, the organization has updated its share capital as part of its at-the-market offering program. On January 31, 2025, Oculis issued 2,500,000 new registered ordinary s...
Shares

Oculis Strengthens Market Position with $100 Million Share Offering Amid Strategic Capital Adjustments,

Published Fri, Feb 14 2025 12:40 AM UTC

Oculis Achieves Successful $100 Million Share Offering Amid Expanding Capital StrategyIn a decisive move highlighting its growing influence in the biopharmaceutical sector, Oculis Holding AG, a global leader in ophthalmic and neuro-ophthalmic treatments, has announced the successful pricing of an oversubscribed public offering. The company confirmed the issuance of 5,000,000...
Stock Market Announcement

Oculis Holding AG Revamps Voting Rights: What This Means for Current and Future Investors,

Published Mon, Jan 20 2025 10:00 PM UTC

Navigating the Shifting Landscape: Oculis Holding AG s Recent Changes in Voting Rights and Their Implications for ShareholdersZUG, Switzerland Oculis Holding AG has recently published a significant press release announcing major changes in its voting rights, effective as of January 20, 2025. The notification signals a pivotal moment for both the company and its shareholde...
Announcement

Oculis Reports Positive Phase 2 ACUITY Trial Results for OCS-05 Amid Mixed Financial Performance

Published Mon, Jan 6 2025 12:24 PM UTC

Oculis Holding AG recently announced promising results from its Phase 2 ACUITY trial for OCS-05, a potential first-in-class neuroprotective therapy aimed at treating acute optic neuritis. The company successfully met its primary safety endpoint as well as key secondary efficacy endpoints in this trial, which opens several development pathways for the drug.Acute optic neuriti...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.79
Working Capital Ratio 6.53
Leverage Ratio (MRQ) 0.2
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.49 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 24,121
Net Income per Employee (TTM) -2,503,022
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.01

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -6811.68 %
Net Margin (MRQ) -8253.3 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Oculis Holding Ag's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.